Metastatic type 1 gastric carcinoid: A real threat or just a myth?

World Journal of Gastroenterology

Volumn 19, Issue 46, 2013, Pages 8687-8695

  Grozinsky Glasberg, Simona ^a   Thomas, Dimitrios ^b   Strosberg, Jonathan R ^c   Pape, Ulrich Frank ^d   Felder, Stephan ^d   Tsolakis, Apostolos V ^e   Alexandraki, Krystallenia I ^b   Fraenkel, Merav ^g   Saiegh, Leonard ^f   Reissman, Petachia ^h   Kaltsas, Gregory ^b   Gross, David J ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF ATHENS   (Greece)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UPPSALA UNIVERSITY   (Sweden)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^g BNAI ZION MEDICAL CENTER   (Israel)

^h HEBREW UNIVERSITY   (Israel)

Author keywords

Chromogranin A; Gastrin; Metastatic gastric carcinoids; Somatostatin analogues; Stomach neuroendocrine tumor

Indexed keywords

ANGIOPEPTIN; CHROMOGRANIN A; CYANOCOBALAMIN; GALLIUM 68; GASTRIN; INDIUM 111; KI 67 ANTIGEN; OCTREOTIDE; PEGINTERFERON ALPHA; PENTETREOTIDE IN 111; PROTON PUMP INHIBITOR; SOMATOSTATIN; TETRAXETAN; TRACER; VESICULAR MONOAMINE TRANSPORTER 2;

ADULT; ARTICLE; ATROPHIC GASTRITIS; AUTOIMMUNE DISEASE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CLINICAL EVALUATION; DIARRHEA; DUMPING SYNDROME; ENDOSCOPY; EVALUATION AND FOLLOW UP; FATIGUE; FEMALE; GASTRECTOMY BILLROTH II; GASTRIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; GASTROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN PRODUCING CELL; INTESTINE METAPLASIA; LIVER METASTASIS; LYMPHADENOPATHY; MALE; METASTATIC GASTRIC CARCINOID TYPE 1; PERNICIOUS ANEMIA; POSITRON EMISSION TOMOGRAPHY; STOMACH TUMOR; TREATMENT RESPONSE; WEDGE RESECTION;

CHROMOGRANIN A; GASTRIN; METASTATIC GASTRIC CARCINOIDS; SOMATOSTATIN ANALOGUES; STOMACH NEUROENDOCRINE TUMOR;

ADULT; AGED; CARCINOID TUMOR; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; EUROPE; FEMALE; GASTRECTOMY; GASTRIC BYPASS; GASTRINS; GASTROSCOPY; HUMANS; ISRAEL; KI-67 ANTIGEN; LIVER NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84890346543     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i46.8687     Document Type: Article

References (36)

1. Gough DB, Thompson GB, Crotty TB, Donohue JH, Kvols LK, Carney JA, Grant CS, Nagorney DM. Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J Surg 1994; 18: 473-479; discussion 479-480 [PMID: 7725731 DOI: 10.1007/ BF00353739]
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959 [PMID: 12569593 DOI: 10.1002/cncr.11105]
3. Fraenkel M, Kim MK, Faggiano A, Valk GD. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2012; 26: 691-703 [PMID: 23582913 DOI: 10.1016/j.bpg.2013.01.006]
4. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340: 858-868 [PMID: 10080850 DOI: 10.1056/NEJM19990 3183401107]
5. Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, Stolte M, Capella C, Bordi C, Solcia E. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999; 116: 532-542 [PMID: 10029611 DOI: 10.1016/ S0016-5085(99)70174-5]
6. Soga J. Gastric carcinoids: a statistical evaluation of 1,094 cases collected from the literature. Surg Today 1997; 27: 892-901 [PMID: 10870573 DOI: 10.1007/BF02388135]
7. Granberg D, Wilander E, Stridsberg M, Granerus G, Skogseid B, Oberg K. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut 1998; 43: 223-228 [PMID: 10189848 DOI: 10.1136/gut.43.2.223]
8. Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985; 88: 638-648 [PMID: 2578420]
9. Ahlman H, Dahlström A, Enerbäck L, Granérus G, Nilsson O, Persson S, Tisell LE. Two cases of gastric carcinoids: diagnostic and therapeutic aspects. World J Surg 1988; 12: 356-361 [PMID: 2456643 DOI: 10.1007/BF01655671]
10. Kölby L, Wängberg B, Ahlman H, Jansson S, Forssell-Aronsson E, Erickson JD, Nilsson O. Gastric carcinoid with histamine production, histamine transporter and expression of somatostatin receptors. Digestion 1998; 59: 160-166 [PMID: 9586830 DOI: 10.1159/000007482]
11. Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, Goede A, Caplin M, Oberg K, Reubi JC, Nilsson O, Delle Fave G, Ruszniewski P, Ahlman H, Wiedenmann B. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394-424 [PMID: 15838182 DOI: 10.1159/000085237]
12. Gilligan CJ, Lawton GP, Tang LH, West AB, Modlin IM. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995; 90: 338-352 [PMID: 7872269]
13. Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery 2004; 136: 1267-1274 [PMID: 15657586 DOI: 10.1016/ j.surg.2004.06.057]
14. Kulke MH. Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin North Am 2007; 21: 433-455; vii-viii [PMID: 17548033]
15. Plöckinger U, Couvelard A, Falconi M, Sundin A, Salazar R, Christ E, de Herder WW, Gross D, Knapp WH, Knigge UP, Kulke MH, Pape UF. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology 2008; 87: 20-30 [PMID: 17934252 DOI: 10.1159/000109876]
16. D'Adda T, Annibale B, Delle Fave G, Bordi C. Oxyntic endocrine cells of hypergastrinaemic patients. Differential response to antrectomy or octreotide. Gut 1996; 38: 668-674 [PMID: 8707110 DOI: 10.1136/gut.38.5.668]
17. Ferraro G, Annibale B, Marignani M, Azzoni C, D'Adda T, D'Ambra G, Bordi C, delle Fave G. Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth. J Clin Endocrinol Metab 1996; 81: 677-683 [PMID: 8636288]
18. Delle Fave G, Annibale B. Modulation of growth of human gastric enterochromaffin-like cells. Digestion 1996; 57 Suppl 1: 15-16 [PMID: 8813460]
19. Higham AD, Dimaline R, Varro A, Attwood S, Armstrong G, Dockray GJ, Thompson DG. Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor. Gastroenterology 1998; 114: 817-822 [PMID: 9516403 DOI: 10.1016/S0016-5085(98)70596-7]
20. Modlin IM, Lawton GP, Miu K, Kidd M, Luque EA, Sandor A, Tang LH. Pathophysiology of the fundic enterochromaffin-like (ECL) cell and gastric carcinoid tumours. Ann R Coll Surg Engl 1996; 78: 133-138 [PMID: 8678447]
21. Grozinsky-Glasberg S, Kaltsas G, Gur C, Gal E, Thomas D, Fichman S, Alexandraki K, Barak D, Glaser B, Shimon I, Gross DJ. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol 2008; 159: 475-482 [PMID: 18662970 DOI: 10.1530/ EJE-08-0420]
22. Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Corinaldesi R, Tomassetti P. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 2008; 15: 337-342 [PMID: 18310299 DOI: 10.1677/ERC-07-0251]
23. Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL. Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol 2004; 39: 621-628 [PMID: 15370681 DOI: 10.1080/00365520410005225]
24. Rindi G, de Herder WW, O'Toole D, Wiedenmann B. Consensus guidelines for the management of patients with digestive neuroendocrine tumors: the second event and some final considerations. Neuroendocrinology 2008; 87: 5-7 [PMID: 17940331 DOI: 10.1159/000109975]
25. Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol 2008; 20: 1-12 [PMID: 18043250 DOI: 10.1097/CCO.0b013e3282f1c595]
26. Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, Sasano H, Tomassetti P, Salazar R, Ruszniewski P. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012; 95: 74-87 [PMID: 22262004 DOI: 10.1159/000335595]
27. Grozinsky-Glasberg S, Grossman AB, Korbonits M. The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol 2008; 286: 238-250 [PMID: 18037561 DOI: 10.1016/j.mce.2007.10.006]
28. Thomas D, Tsolakis AV, Grozinsky-Glasberg S, Fraenkel M, Alexandraki K, Sougioultzis S, Gross DJ, Kaltsas G. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol 2013; 168: 185-193 [PMID: 23132699 DOI: 10.1530/EJE-12-0836]
29. Vitale G, de Herder WW, van Koetsveld PM, Waaijers M, Schoordijk W, Croze E, Colao A, Lamberts SW, Hofland LJ. IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Res 2006; 66: 554-562 [PMID: 16397272 DOI: 10.1158/0008-5472. CAN-05-3043]
30. Vitale G, van Koetsveld PM, de Herder WW, van der Wansem K, Janssen JA, Colao A, Lombardi G, Lamberts SW, Hofland LJ. Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. Am J Physiol Endocrinol Metab 2009; 296: E559-E566 [PMID: 19141687 DOI: 10.1152/ajpendo.90770.2008]
31. Caraglia M, Marra M, Tagliaferri P, Lamberts SW, Zappavigna S, Misso G, Cavagnini F, Facchini G, Abbruzzese A, Hofland LJ, Vitale G. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets 2009; 9: 690-704 [PMID: 19508175 DOI: 10.2174/156800909789056980]
32. Kidd M, Modlin IM, Black JW, Boyce M, Culler M. A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation. Regul Pept 2007; 143: 109-117 [PMID: 17531331 DOI: 10.1016/j.regpep.2007.04.002]
33. Wolin EM, Hu K, Hughes G, Bouillaud E, Giannone V, Resendiz KH. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study. Cancer Chemother Pharmacol 2013; 72: 387-395 [PMID: 23765178 DOI: 10.1007/ s00280-013-2202-1]
34. Saund MS, Al Natour RH, Sharma AM, Huang Q, Boosalis VA, Gold JS. Tumor size and depth predict rate of lymph node metastasis and utilization of lymph node sampling in surgically managed gastric carcinoids. Ann Surg Oncol 2011; 18: 2826-2832 [PMID: 21455598 DOI: 10.1245/ s10434-011-1652-0]
35. Weck MN, Stegmaier C, Rothenbacher D, Brenner H. Epidemiology of chronic atrophic gastritis: population-based study among 9444 older adults from Germany. Aliment Pharmacol Ther 2007; 26: 879-887 [PMID: 17767472 DOI: 10.1111/j.1365-2036.2007.03430.x]
36. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95: 98-119 [PMID: 22261919 DOI: 10.1159/000335591]